Ripretinib
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Ripretinib: From Gastrointestinal Stromal Tumor to Multiple Endocrine Neoplasia
One-Sentence Summary
Ripretinib is a KIT/PDGFRA switch-control kinase inhibitor used as a fourth-line treatment for gastrointestinal stromal tumor (GIST). The TxGNN model’s top prediction — Multiple Endocrine Neoplasia (MEN) — scores highly (98.84%), but is supported by zero clinical trials and zero publications, and the evidence pack itself flags the mechanistic rationale as likely a knowledge-graph false positive, since MEN is driven by RET/MEN1 mutations with no known link to the KIT/PDGFRA pathway.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Gastrointestinal Stromal Tumor (GIST), 4th-line — inferred from mechanistic rationale text; no structured EU authorization data available |
| Predicted New Indication | Multiple Endocrine Neoplasia |
| TxGNN Prediction Score | 98.84% |
| Evidence Level | L5 |
| EU Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in structured form (flagged as a High-severity data gap). Based on known pharmacology referenced in the evidence pack’s rationale, ripretinib is a switch-control tyrosine kinase inhibitor targeting KIT and PDGFRA, approved as a fourth-line therapy for GIST.
The top-ranked prediction, multiple endocrine neoplasia, is driven by RET mutations (MEN2) or MEN1 gene loss, neither of which has an established mechanistic connection to KIT/PDGFRA signaling. The evidence pack’s own repurposing rationale explicitly states this link is “weak” and “may be a knowledge-graph embedding false positive” — there is no supporting clinical or preclinical evidence.
This skepticism extends across the full set of 10 predicted indications reviewed: HER2-positive and hormone-receptor-defined breast cancer subtypes (driven by ERBB2/ER/PR pathways, unrelated to KIT/PDGFRA), two veterinary bovine viral diseases (infectious bovine rhinotracheitis, malignant catarrh — flagged as species-mismatch noise from a model trained partly on non-human data), cytomegalovirus infection (no antiviral mechanism), and amenorrhea (no established mechanistic link). Notably, the 19 literature records retrieved for “breast tumor luminal A or B” are B-cell immunology and Hepatitis B vaccine papers — a keyword-matching artifact on the letter “B,” not genuine evidence. None of the 10 candidates in this pack currently clear even preliminary mechanistic plausibility screening.
Clinical Trial Evidence
Currently no related clinical trials registered for the top-ranked predicted indication (Multiple Endocrine Neoplasia).
Literature Evidence
Currently no related literature available for the top-ranked predicted indication (Multiple Endocrine Neoplasia).
EU Market Information
Ripretinib currently holds no EU marketing authorizations (0 licenses on file; market status: Not marketed).
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (KIT/PDGFRA switch-control tyrosine kinase inhibitor) |
| Myelosuppression Risk | Please refer to the SmPC warnings and precautions |
| Emetogenicity Classification | Please refer to the SmPC warnings and precautions |
| Monitoring Items | Please refer to the SmPC warnings and precautions |
| Handling Protection | Please refer to the SmPC warnings and precautions |
Safety Considerations
Please refer to the SmPC for safety information. (Key warnings, contraindications, and drug-interaction data are currently unavailable — TFDA/EMA label data collection is a blocking gap in this evidence pack.)
Conclusion and Next Steps
Decision: Hold
Rationale: All 10 predicted indications in this pack are Evidence Level L5 (AI prediction only, no clinical or trial support), and the top-ranked candidate (MEN) is explicitly flagged within the evidence pack as a likely mechanistic false positive with no known pathway overlap. The drug also has no EU marketing authorization and no confirmed structured MOA/safety data, so it cannot advance past S0.
To proceed, the following is needed:
- Regulatory label data (warnings, contraindications) — currently a blocking data gap (DG001)
- Confirmed structured mechanism of action data (DG002)
- Independent literature/trial search specifically for MEN, RET, or MEN1 to test (or refute) the mechanistic hypothesis before any further screening
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.